| Literature DB >> 34569332 |
Gregory S Kazarian1, Michael E Steinhaus1, Han Jo Kim1.
Abstract
STUDY DESIGN/Entities:
Year: 2021 PMID: 34569332 PMCID: PMC9393993 DOI: 10.1177/21925682211026630
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Study Quality Assessment.
| Were participants analyzed within the groups they were originally assigned to? | Did the study apply inclusion/exclusion criteria uniformly to all comparison groups? | Did the strategy for recruiting participants into the study differ across study groups? | Does the design or analysis control account for important confounding and modifying variables through matching, stratification, multivariable analysis, or other approaches? | Did researchers rule out any impact from a concurrent intervention or an unintended exposure that might bias results? | Did the study maintain fidelity to the intervention protocol? | If attrition (overall or differential nonresponse, dropout, loss to follow-up, or exclusion of participants) was a concern, were missing data handled appropriately (e.g., intention-to-treat analysis and imputation)? | In prospective studies, was the length of follow-up different between the groups, or in case-control studies, was the time period between the intervention/exposure and outcome the same for cases and controls? | Were the outcome assessors blinded to the intervention or exposure status of participants? | Were interventions/exposures assessed/defined using valid and reliable measures, implemented consistently across all study participants? | Were outcomes assessed/defined using valid and reliable measures, implemented consistently across all study participants? | Were confounding variables assessed using valid and reliable measures, implemented consistently across all study participants? | Were the potential outcomes prespecified by the researchers? Are all prespecified outcomes reported? | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Farshad et al
| Yes | Yes | No | Yes | Unknown | Yes | Yes | No | Unknown | Yes | Yes | Yes | Yes |
| Hartveldt et al
| Yes | Yes | No | Yes | Unknown | Yes | Yes | No | Unknown | Yes | Yes | Yes | Yes |
| Pisano et al
| Yes | Yes | No | No | Unknown | Yes | Yes | No | Unknown | Yes | Yes | No | Yes |
| Seavey et al
| Yes | Yes | No | Yes | Unknown | Yes | Yes | No | Unknown | Yes | Yes | Yes | Yes |
| Singla et al
| Yes | Yes | No | Yes | Unknown | Yes | Yes | No | Unknown | Yes | Yes | Yes | Yes |
| Yang et al
| Yes | Yes | No | Yes | Unknown | Yes | Yes | No | Unknown | Yes | Yes | Yes | Yes |
Figure 1.PRISMA flow diagram. A total of 6 studies were included in the final systematic review.
Summary of Studies Included in the Systematic Review.
| Author | Country of publication | Year of publication | LOE | Timing of CSI | n= | Injection type | Procedure | Instrumented? | Data source |
|---|---|---|---|---|---|---|---|---|---|
|
| Switzerland | 2018 | III | 0-3 mos. | Cases: 10 | ESI or Facet | Lumbar decompression +/−fusion | Did not stratify | Swiss Lumbar Stenosis Outcomes Study database |
|
| USA | 2016 | III | 0-1 mos. | Injx: 945 | ESI | Lumbar laminectomy +/−fusion | Did not stratify | Institutional database |
|
| USA | 2020 | III | 0-1 mos. | Injx: 612 | ESI (348) or Facet (264) | Lumbar fusion | Did not stratify | Military Health System Data Repository |
|
| USA | 2017 | III | 0-1 mos. | Injx: 847 | ESI | Lumbar decompression (1-level) | No | Military Health System Data Repository |
|
| USA | 2017 | IV | 0-1 mos. | Cases: 1,411 | ESI | Lumbar fusion (1-or 2-level) | Did not stratify | PearlDiver |
|
| USA | 2016 | III | 0-1 mos. | Injx: 18 931 | ESI | Lumbar decompression (1-level) | No | PearlDiver |
Abbreviations: LOE = Level of evidence; CSI = Corticosteroid spinal injection; Injx = Injection; ESI = Epidural spinal injection; ACDF = Anterior cervical discectomy and fusion; PCF = Posterior cervical fusion.
Summary of Results.a
| Author | Outcomes | Conclusion |
|---|---|---|
|
| 0-3 mos.: OR = 0.36, 95% CI 0.04-3.22 | No significant association between infection or wound-healing problems and CSI timing. |
|
| 0-1 mos.: OR = 0.79, 95% CI 0.31-1.96, | No significant association between infection and CSI timing. |
|
| 0-1 mos.: OR = 0.0, 95% CI 0.00-8.41, | No significant association between infection and CSI timing, type, or number of injections. |
|
| 0-1 mos.: OR = 0.79, 95% CI 0.02-4.71, | No significant association between infection and CSI timing. |
|
| 0-1 mos.: OR = 2.6, 95% CI 2.0-3.3, | CSI <3 months before surgery led to a significant increase in the risk of infection. |
|
| 0-1 mos.: OR = 3.2, 95% CI 2.3-4.6, | ESI <3 months before single-level lumbar decompression increases the risk of infection. |
Abbreviations: CSI = Corticosteroid spinal injection; ESI = Epidural spinal injection; OR = Odds ratio; CI = Confidence interval.
a* = statistically significant.
Summary of Data Included in the Meta-Analysis.
| Study | Infections in CSI | N = (CSI) | % Infections in CSI | Infections in control | N = (Control) | % Infections in control |
|---|---|---|---|---|---|---|
|
| ||||||
|
| 5 | 290 | 1.7% | 129 | 5,021 | 2.6% |
|
| 0 | 31 | 0.0% | 43 | 2,791 | 1.5% |
|
| 1 | 167 | 0.6% | 43 | 5,688 | 0.8% |
|
| 66 | 1,699 | 3.9% | 1,059 | 70 857 | 1.5% |
|
| 38 | 2,261 | 1.7% | 192 | 36 586 | 0.5% |
|
| ||||||
|
| 19 | 945 | 2.0% | 115 | 4,366 | 2.6% |
|
| 0 | 170 | 0.0% | 43 | 2,791 | 1.5% |
|
| 6 | 485 | 1.2% | 43 | 5,688 | 0.8% |
|
| ||||||
|
| 2 | 158 | 1.3% | 43 | 2,791 | 1.5% |
|
| 3 | 202 | 1.5% | 43 | 5,688 | 0.8% |
|
| 136 | 10 493 | 1.3% | 1,148 | 70 857 | 1.6% |
|
| 58 | 7,017 | 0.8% | 148 | 23 236 | 0.6% |
CSI = Corticosteroid spinal injection.
Results of Meta-Analysis. Summary of Meta Analysiis.
| CSI timing | % Infections (CSI) | % Infections (control) | I
| RR (95% CI) | |
|---|---|---|---|---|---|
|
| 2.5% | 1.2% | 67.23a | 1.986 (1.202-3.282) | 0.007b |
|
| 1.6% | 1.6% | 0.00 | 0.887 (0.586-1.341) | 0.569 |
|
| 1.1% | 1.3% | 66.80a | 1.053 (0.704-1.575) | 0.802 |
Abbreviations: CSI = Corticosteroid spinal injection; RR = Relative risk; CI = Confidence interval.
a indicates a statistically significant level of heterogeneity, necessitating a random-effects model; bindicates a statistically significant difference between the CSI and control groups in the meta-analysis.
Figure 2.Forest plot comparing the risk of postoperative spine infection following CSI <1 month preoperative compared to controls.
Figure 3.Forest plot comparing the risk of postoperative spine infection following CSI 0-3 months preoperative compared to controls.
Figure 4.Forest plot comparing the risk of postoperative spine infection following CSI 3-6 months preoperative compared to controls.
“Leave-Out” Meta-Analysis for the CSI <1 Month Preoperative Grouping.
| Study | RR (95% CI) | |
|---|---|---|
|
| 2.737 (2.246-3.335) | <0.001 |
|
| 2.009 (1.188-3.397) | 0.009 |
|
| 2.102 (1.258-3.511) | 0.005 |
|
| 1.321 (0.428-4.074) | 0.628a |
|
| 1.271 (0.475-3.397) | 0.633a |
Abbreviations: CSI = Corticosteroid spinal injection; RR = Relative risk; CI = Confidence interval.
a indicates a change in the statistical significance of the meta-analysis when the results of this study were eliminated from the assessment.